Skip to content
20-F

Annual Report (Foreign)

Quantum BioPharma Ltd. QNTM

0001185185-26-001069

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow FY 2025 · Dec 31, 2025 −$8.24M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.91M
Cash And Equivalents FY 2025 · Dec 31, 2022 $16.98M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.1M
Current Liabilities FY 2025 · Dec 31, 2025 $6.06M
Total Liabilities FY 2025 · Dec 31, 2025 $6.06M
Current Assets FY 2025 · Dec 31, 2025 $6.48M
Total Assets FY 2025 · Dec 31, 2025 $11.16M
Sga Expense FY 2025 · Dec 31, 2025 $9.05M
Sga Expense FY 2025 · Dec 31, 2024 $9.41M
Sga Expense FY 2025 · Dec 31, 2023 $9.03M
Rd Expense FY 2025 · Dec 31, 2025 $2.76M
Operating Income FY 2025 · Dec 31, 2025 −$15.3M
Operating Income FY 2025 · Dec 31, 2024 −$16.14M
Operating Income FY 2025 · Dec 31, 2023 −$23.79M